MOR - Incyte/MorphoSys' tafasitamab Canada application accepted for review

Health Canada has accepted for review Incyte (INCY) and MorphoSys' (MOR) marketing application seeking approval for tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.Last year, both the companies teamed up to further develop and commercialize anti-CD19 monoclonal antibody, in $2B deal.The FDA approved tafasitamab-cxix combined with lenalidomide, for the same indication, in April last year.

For further details see:

Incyte/MorphoSys' tafasitamab Canada application accepted for review